{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062943","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.379452+00:00","generated_at":"2026-06-08T05:02:47.067489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annexon Q3 net loss $32.5M, cash $165.3M; Phase 3 GBS enrollment complete, data H1 2024","bullets":["Net loss of $32.5M ($0.43 per share) vs $35.1M ($1.42 per share) in Q3 2022.","Cash, equivalents and investments of $165.3M as of Sep 30, 2023; runway into Q2 2025.","R&D expenses flat at $27.9M; G&A down to $6.9M from $8.2M.","Phase 3 GBS trial enrolled 225 patients; topline pivotal data expected first half 2024.","ANX007 for GA granted EMA PRIME designation; global Phase 3 regulatory discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062943","json":"https://secwatch.observer/filing/0000950170-23-062943.json","markdown":"https://secwatch.observer/filing/0000950170-23-062943.md","text":"https://secwatch.observer/filing/0000950170-23-062943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023062943/0000950170-23-062943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017023062943/annx-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:02:47.067489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}